Withdrawn × OTHER × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Clear all Difficult PIV Placement in the Pediatric ED
Phase NA Withdrawn
Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT
Phase 1 Withdrawn
Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma
Phase 1 Withdrawn
Pain Control Differences Between Oxycodone and Ibuprofen in Children With Isolated Forearm Injuries
Phase NA Withdrawn
Continuous Ambulatory Monitoring to Predict Elevated Risk of Infection in Children With Lymphoblastic Leukemia Undergoing Induction Chemotherapy (CAMPER-ALL)
Withdrawn
Antimicrobial Revision in Persistent Febrile Neutropenia
Phase 4 Withdrawn
Taking POSNA's OrthoKids to the People
Phase NA Withdrawn
HEM-iSMART A
Phase 1/2 Withdrawn
High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD
Phase 1/2 Withdrawn
DLI-TARGET
Phase 2 Withdrawn
Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Phase 2 Withdrawn
A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies
Phase 1/2 Withdrawn
Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias
Phase 1 Withdrawn
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer
Phase 1/2 Withdrawn
Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma
Phase 1 Withdrawn
Femoral Pediatric Fractures. Walking Spica Cast vs Synthetic Pants
Phase NA Withdrawn
Patient Satisfaction in the Orthopedic Surgery Clinic
Phase NA Withdrawn
2019-KOE-001
Phase 2 Withdrawn
CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA)
Phase 1 Withdrawn
Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT
Phase 3 Withdrawn
The Value of Follow-Up After Childhood Acute Lymphoblastic Leukaemia in Denmark - Family Perspectives
Withdrawn
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer
Phase 1 Withdrawn
Infusion of Allogeneic, 3rd Party CD19-specific T Cells
Phase 1 Withdrawn
Bone Marrow Transplantation in Treating Patients With Leukemia
Phase 3 Withdrawn
Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma
Phase 2 Withdrawn
Intravenous Zoledronic Acid for the Treatment of Osteoporosis and Osteonecrosis in Children With Leukemia: A Pilot Study
Phase 2 Withdrawn
Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies
Phase 2 Withdrawn
Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR)
Phase 1 Withdrawn
StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies
Phase 2 Withdrawn
T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies
Phase 1/2 Withdrawn
Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia
Phase 2 Withdrawn
Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
Phase 2 Withdrawn
COMBOSTAT
Phase 2 Withdrawn
Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or Older
Phase 1 Withdrawn
Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase 1 Withdrawn
Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
Phase 1/2 Withdrawn
Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who Have Undergone Organ Transplants
Phase 1 Withdrawn
Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma
Phase NA Withdrawn
Prevention of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Receiving a Bone Marrow Transplant
Phase 1/2 Withdrawn
Early Detection of Graft-Versus-Host Disease in Patients Undergoing a Donor Bone Marrow Transplant
Withdrawn
Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 1 Withdrawn
IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)
Phase 2 Withdrawn
Study of Sirolimus With PEG-Asparaginase in Acute Lymphoblastic Leukemia (ALL)
Phase 1 Withdrawn
Antiviral Therapy Plus Either Peripheral Stem Cell or Umbilical Cord Blood Transplantation in Treating Patients Who Are HIV Positive and Have Hematologic Cancer
Phase 1 Withdrawn
Bendamustine in Acute Lymphoblastic Leukemia/Lymphoma (ALL)
Phase 2 Withdrawn
Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Phase 2 Withdrawn
Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant
Phase NA Withdrawn
Ovarian Damage in Young Premenopausal Women Undergoing Chemotherapy for Cancer
Withdrawn
Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection
Phase NA Withdrawn